Updated on 5 August 2016
Singapore: Opening a new window for export earnings, Bangladesh's Beximco pharmaceuticals recently announced that they had commenced the export of hypertensive drug, Carvedilol to the United States, one of the most regulated markets in the world.
The drug treats hypertension and this is the first time a pharmaceutical product made in Bangladesh has hit the American market. Finance Minister Abul Maal Abdul Muhith said at the launch in Dhaka that the decades old company had "achieved glory for us."
At a recent ceremony, the company's Vice-Chairman Mr Salman F Rahman,said, "As we deliver our first shipment of Carvedilol to the US market, we begin a new era for the pharmaceutical industry in Bangladesh.We believe our continued focus on building and strengthening the group's presence in the western markets will cement Bangladesh's position as a major exporting country."
Health Minister Mohammed Nasim also congratulated the company and said," We must celebrate the glory." Highlighting that receiving a USFDA approval was a rigorous process, the US Ambassador Ms Marcia Bernicat said it was "a testament to Beximco's hard work as well as the quality of their products". "I am especially proud that US consumers will now be able to take a life-saving drug and see ‘made in Bangladesh' on the bottle."
Mr Nazmul Hassan, managing director of Beximco Pharma, said the US is the largest and most lucrative pharmaceutical market in the world. "As a leading exporter of medicines, we strive to capitalise on the generic drug opportunities in the world market."We believe our competitive products, especially with specialised and differentiated generic products, will help strengthen our presence in the US and other advanced markets," he added.